Angioplasty Balloons Market by Type of Balloons (Drug-Eluting Angioplasty Balloons, Non-Drug Eluting Angioplasty Balloons, Cutting Balloons), by Application (Coronary Artery Disease, Peripheral Artery Disease, Renal Artery Disease), by End-User (Hospitals, Ambulatory Surgical Centers); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Angioplasty Balloons Market was valued at USD 3.4 Billion in 2023 and will surpass USD 7.1 Billion by 2030; growing at a CAGR of 10.9% during 2024 - 2030.

The angioplasty balloons market is a crucial segment in the global medical devices industry, focusing on the treatment of cardiovascular diseases, particularly arterial blockages. Angioplasty balloons are used during percutaneous transluminal angioplasty (PTA) procedures to open narrowed or obstructed blood vessels, typically in the coronary, peripheral, or renal arteries. As the global prevalence of cardiovascular diseases (CVDs) increases, along with a growing aging population and a rise in lifestyle-related health conditions, the demand for angioplasty procedures is steadily growing. The market is also driven by technological advancements, such as the development of drug-eluting and cutting balloons that offer enhanced outcomes in arterial interventions.

In addition to traditional balloon technologies, the market is witnessing innovations such as drug-eluting balloons (DEBs), which deliver drugs directly to the site of blockage to reduce restenosis and improve long-term patient outcomes. These innovations are expected to shape the future of the angioplasty balloons market, expanding the applications and treatment options available for cardiovascular patients.

Drug-Eluting Angioplasty Balloons Segment is Largest Owing to Improved Clinical Outcomes

The drug-eluting angioplasty balloons segment is the largest in the angioplasty balloons market due to the growing preference for these balloons over traditional non-drug eluting types. Drug-eluting balloons are designed to release medication that helps prevent restenosis, or the re-narrowing of the artery, a common complication after angioplasty procedures. These balloons deliver localized treatment directly to the affected area, reducing the need for additional interventions and improving the long-term success of the procedure.

Drug-eluting angioplasty balloons have gained widespread adoption among healthcare professionals because they offer a dual benefit: the mechanical dilation of the artery and the pharmacological action of the drug to reduce inflammation and promote healing. The increasing number of patients with coronary artery disease and peripheral artery disease, coupled with the effectiveness of drug-eluting balloons in improving clinical outcomes, has led to their dominance in the market. As the technology continues to improve, with advancements in drug formulations and balloon coatings, the segment is expected to maintain its leadership position in the angioplasty balloons market.

Coronary Artery Disease Segment is Largest Application Owing to High Prevalence of Cardiovascular Disorders

The coronary artery disease (CAD) segment is the largest application within the angioplasty balloons market, owing to the high prevalence of CAD worldwide. CAD is a leading cause of death globally, driven by risk factors such as hypertension, high cholesterol, diabetes, and smoking. The increasing incidence of CAD, particularly among aging populations, has significantly contributed to the demand for angioplasty procedures, including those involving angioplasty balloons. The rising need for effective treatments for CAD has made coronary artery interventions a key focus of the market.

Angioplasty balloons are extensively used in CAD treatments to open narrowed or blocked coronary arteries, restoring blood flow to the heart and reducing the risk of heart attacks. As coronary artery disease continues to be a major healthcare burden, the demand for angioplasty balloons is projected to grow steadily. Furthermore, advancements in drug-eluting balloon technologies, which provide better long-term results and reduce the risk of restenosis, are expected to further drive growth in this segment.

Hospitals Segment is Largest End-User Owing to High Procedure Volumes

Hospitals remain the largest end-user of angioplasty balloons, owing to the high volume of angioplasty and related cardiovascular procedures performed in these settings. Hospitals, especially large medical centers and cardiac care units, are equipped with the advanced medical infrastructure required to perform complex angioplasty procedures. The large number of cardiac interventions conducted in hospitals worldwide, including those for coronary artery disease, peripheral artery disease, and renal artery disease, makes them the primary consumers of angioplasty balloons.

Hospitals offer comprehensive care for patients undergoing angioplasty, with specialized teams including cardiologists, interventional radiologists, and cardiac surgeons. The presence of skilled professionals and cutting-edge facilities, along with a high incidence of cardiovascular disease, makes hospitals the primary end-users of angioplasty balloons. The continuous demand for angioplasty procedures, coupled with hospitals’ ability to invest in advanced medical technologies, ensures that they will maintain their position as the largest end-user segment in the market.

North America is Largest Region Owing to Advanced Healthcare Systems

North America is the largest region in the angioplasty balloons market, driven by its advanced healthcare infrastructure, high healthcare spending, and high adoption of advanced medical technologies. The United States, in particular, is the dominant player in the North American market due to its well-established healthcare system and high rates of coronary artery disease and peripheral artery disease. The region also benefits from a large number of hospitals and surgical centers specializing in cardiovascular treatments, where angioplasty balloon procedures are commonly performed.

In addition to the established healthcare infrastructure, North America benefits from a strong regulatory framework that ensures the quality and safety of medical devices, including angioplasty balloons. The region's leading position is further supported by the increasing number of angioplasty procedures and the growing awareness of the benefits of drug-eluting balloons. As the prevalence of cardiovascular diseases continues to rise, North America is expected to maintain its dominance in the angioplasty balloons market.

Competitive Landscape and Leading Companies

The angioplasty balloons market is highly competitive, with several prominent players driving innovation and shaping the industry. Leading companies in this market include Medtronic, Boston Scientific, Abbott Laboratories, Terumo Corporation, and Biotronik. These companies are at the forefront of developing advanced angioplasty balloons, including drug-eluting and cutting balloons, to cater to the growing demand for effective cardiovascular treatments.

The competitive landscape is characterized by ongoing research and development aimed at improving balloon technologies, reducing complications, and enhancing patient outcomes. Companies are investing heavily in the development of new drug formulations, better coating technologies, and balloon designs to improve performance and safety. Additionally, strategic partnerships, acquisitions, and collaborations with healthcare providers are common strategies employed by key players to strengthen their market position. As the market continues to grow, the focus on innovation, patient safety, and regulatory compliance will intensify, leading to further competition and technological advancements in the angioplasty balloons market.

ist of Leading Companies:

• Abbott Laboratories
• B. Braun Melsungen AG
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Medical
• Cordis Corporation (Johnson & Johnson)
• Integer Holdings Corporation
• Medinol Ltd.
• Medtronic PLC
• MicroPort Scientific Corporation
• Raumedic AG
• Smith & Nephew PLC
• Surmodics, Inc.
• Terumo Corporation
• Vascular Solutions

Recent Developments:

• Medtronic PLC launched a new advanced angioplasty balloon that improves precision in treating coronary artery disease with reduced risk of complications.
• Boston Scientific received FDA approval for its new drug-eluting angioplasty balloon that delivers a unique combination of drugs to prevent restenosis after angioplasty.
• Abbott Laboratories completed the acquisition of a competitor in the balloon catheter market to expand its portfolio and strengthen its presence in the interventional cardiology sector.
• Terumo Corporation launched a cutting-edge non-drug-eluting angioplasty balloon designed for minimally invasive vascular procedures in both coronary and peripheral arteries.
• B. Braun Melsungen AG announced a strategic partnership with a major hospital network to offer advanced angioplasty balloons as part of a new interventional cardiology initiative.

Report Scope: